key: cord-1012656-bo88vjes
authors: D’Abramo, Alessandra; Vita, Serena; Maffongelli, Gaetano; Mariano, Andrea; Agrati, Chiara; Castilletti, Concetta; Goletti, Delia; Ippolito, Giuseppe; Nicastri, Emanuele
title: Prolonged and severe SARS-CoV-2 infection in patients under B-cell-depleting drug successfully treated: a tailored approach
date: 2021-04-24
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2021.04.068
sha: 995d6ff3b539782fd28f194a4a32c08e87e45118
doc_id: 1012656
cord_uid: bo88vjes

Prolonged B-cell depletion due to anti-CD20 monoclonal antibody (mAbs) therapy impairs the adaptive immune response causing severe manifestations during COronaVIrus Disease-2019. The cases of two patients under anti-CD20 therapy who experienced prolonged and severe COVID-19 successfully treated with mAbs against Severe Acute Respiratory Syndrome-CoV-2 spike proteins were reported.

Patients with pre-existing comorbidities and immunosuppression including anti-CD20 monoclonal antibody, widely used for the treatment of haematological malignancies or autoimmune disease, are at greater risk for persistent Severe Acute Respiratory Syndrome-CoronaVirus-2 (SARS-CoV-2) infection (He et al,2020) . Prolonged B-cell depletion impairs the adaptive immune response and the ability to produce neutralizing antibodies causing severe manifestations and prolonged course of COVID-19 (Mehta et al, 2020 , Hueso et al, 2020 . Here, we report the cases of two patients under anti-CD20 therapy who experienced prolonged and severe COVID-19 successfully treated with casirivimab and imdevimab mAbs against Severe Acute Respiratory Syndrome-CoV-2 (SARS-CoV- 

The frequency of B (CD19 + ), T (CD3 + ), CD4 + and CD8 + T cells as well as the expression of CD38 on CD4 + and CD8 + T cells was evaluated in the peripheral blood and in BAL by flow cytometry (OneFlow LST tube, BD Biosciences). The frequency of Spike specific T-cells was quantified by ELISpot assay (Mabtech). Briefly, peripheral blood mononuclear cells (PBMC) were isolated and stimulated for 20 hours with peptides overlapping the S protein (0.1ug/ml, Miltenyi Biotech) and with PHA as a positive control. At the end of incubation, the assay was developed according to manufacturer's instruction. Results are shown as spot forming cells (CFS) per million PBMC.

Finally, inflammatory cytokines (IL-1β, IL-6, IL-8, TNF-α) were quantified by automatic ELISA (ELLA, Biotechne).

For microneutralization test, patients' sera were heat-inactivated, diluted 1:10 in serum-free medium, and titrated in duplicate in two-fold dilutions. Equal volumes of 100 TCID50/well SARS-CoV-2 (2019-nCoV/Italy-INMI1; GISAID accession ID: EPI_ISL_412974) and serum dilutions were mixed and incubated at 37°C for 30 minutes. Virus-serum mixtures were added to sub-confluent Vero E6 cells and incubated at 37 °C and 5% CO2 for two days. Then, a Crystal Violet 2% Formaldehyde solution was added to each well and removed after 30 minutes. Cytopathic effect was measured by 

A 54-year-old female patient (pt1) with a history of multiple sclerosis treated with ocrelizumab since December 2018 (last administration on July 2020) and a 54-year-old male patient (pt2) with a diagnosis of a stage 4 follicular lymphoma, treated with a single chemotherapy cycle followed by rituximab on October 2020, are described.

Pt1 was diagnosed a pauci-symptomatic SARS-COV-2 infection with a nasopharyngeal swabs on 

On December 31 th , non-invasive ventilation, antiviral (iv remdesivir) and SARS-CoV-2-mAbs (casirivimab and imdevimab, single iv infusion of 1200 mg of both drugs) were prescribed. After seven days, non-invasive ventilation was discontinued and steroid therapy progressively tapered with marked improvement of clinical conditions until discharge. After mAbs treatment, T-cell subsets came back to a normal CD4/CD8 T-cell ratio (figure 1C/5) and a significant decreased CD4 and CD8

T-cell activation (figure 1C/6) and plasmatic IL-6 (figure 1C/8) were observed. Moreover, a weak spike-specific T-cells response was observed before and early after mAbs treatment that significant ly increased after 10 days from the treatment initiation ( figure 1C/7) . The low T-cell response before treatment, together with the lack of B-cells with consequent absence of Ab response, may be at least partially responsible for a high SARS-CoV-2 titre observed in this patient. Immediately after treatment, neutralizing antibodies reached a titre ≥1:640 and remained stable until the last follow-up (supplementary data). Patient, fully recovered, was discharged with negative SARS-CoV-2 respiratory samples on day 60.

Risk factors associated with severe COVID-19 include older age, male sex, and comorbidities such as obesity, diabetes, hypertension, coronary heart disease, chronic pulmonary or kidney disease (Williamson et al, 2020) . Immunocompromised patient such as cancer and haematological malignancies or patients receiving immunosuppressive drugs appear to be at higher risk of severe 

Risk of tuberculosis reactivation associated with traditional disease modifying anti-rheumatic drugs and non-anti-tumor necrosis factor biologics in patients with rheumatic disorders and suggestion for clinical practice

Rituximab for the treatment of multiple sclerosis: a review

Virological characterization of the first two COVID-19 patients diagnosed in Italy: phylogenetic analysis, virus shedding profile from different body sites and antibody response kinetics

Primary T-cell expansion and differentiation in vivo requires antigen presentation by B-cells

Rituximab in patients with primary progressive multiple sclerosis: results of a randomized doubleblind placebo-controlled multicenter trial

COVID-19 in persons with haematological cancers

Convalescent plasma therapy for B-cell depleted patients with protracted COVID-19

COVID-19 in ocrelizumab-treated people with multiple sclerosis

Mild clinical manifestations of SARS-CoV-2 related pneumonia in two patients with multiple sclerosis under treatment with ocrelizumab

Effectiveness of remdesivir for the treatment of hospitalized COVID-19 persons: A network meta-analysis

B-cell depletion with rituximab in the COVID-19 pandemic: where do we stand? The Lancet Rheumathology

Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity

Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis

REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19

Factors associated with COVID-19-related death using OpenSAFELY